Merck KGaA’s expanded AI deal; Ascletis has new biomarker data for its PD-L1; Deka closes $20M round

Merck KGaA continues AI-powered deal streak: Merck KGaA has expanded its collaboration with Israeli company Quris-AI, with an eye to identifying liver toxicity risks in select drug candidates. The German drugmaker now has the option to exercise an exclusive license to a specific disease domain for up to five years. Merck KGaA recently announced new AI drug discovery partnerships with BenevolentAI and Exscientia. — Ayisha Sharma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Asbestos exposure linked to higher incidence of lung cancers in naval personnel

A University of Adelaide and Oxford University study has discovered asbestos exposure led to a higher incidence of asbestos-related lung cancers in British and Australian

November 14, 2023

Gene-Expression Profiling Can Help Improve Outcomes in Cancers of Unknown Primary

Site-specific therapy guided by gene-expressing profiling (GEP) could improve outcomes for patients with previously untreated cancers of unknown primary (CUP), Chinese researchers suggested. In their

July 31, 2024

Pre-COPD Current and Former Smokers Not in the Clear for Airway Disease

Whether they had respiratory symptoms or not, former and current smokers who didn’t meet criteria for chronic obstructive pulmonary disease (COPD) had similar declines in

August 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.